About
Investigators
Cores
Cell Sourcing
Contact Information
7/13/2016
The ultimate impediment to a cure for HIV infection is the presence of latent, HIV-infected cells, which can reawaken and produce new virus when antiretroviral drug therapy is stopped. These latent, HIV-infected cells are untouched by antiretroviral therapy and are unseen by the immune system.
6/17/2016
Public policy experts, including Dr. Brian Custer from Blood Systems Research Institute, explain the science and research still needed for the US Food & Drug Administration to consider lifting the permanent deferral of MSM from donating blood.
4/11/2016
OTTAWA, ON – Scientists from Blood Systems Research Institute in San Francisco, California, and Canadian Blood Services’ Centre for Innovation lab in Edmonton, Alberta, report for the first time that specific red blood cell manufacturing methods may be less damaging to cells than others. This finding could help reduce adverse reactions in transfusion recipients and may impact the future of how blood is collected in North America and around the world.
4/1/2016
Spurred by three decades of momentum and fresh funding, scientists mount a major effort to finally defeat AIDS.
1/27/2016
“Under Larry’s direction, BSRI-Denver will be an important participant and contributor in the development and evaluation of new methods, devices and biological products in transfusion medicine,” said Michael Busch, M.D., Ph.D., Blood Systems Senior Vice President for Research and Scientific Programs and BSRI Co-Director. “BSRI has a strong reputation for innovative scientific research and policy development, built over more than half a century. The Denver initiative, with Larry’s leadership and Bonfils’ exceptional facilities, brings BSRI squarely into the development arena of R&D with the practical application of scientific knowledge to make a real difference in the lives of patients who receive transfusions.”
12/10/2015
Funded by grants from the National Institutes of Health, scientists at Blood Systems Research Institute (BSRI) in San Francisco and the Washington University School of Medicine in St. Louis have found that neutralizing antibodies that engage epitopes including residue E2-W64 are highly potent at inhibiting the virus in mice, due to the importance of E2-W64 in pathogenicity. Furthermore, these antibodies prevent CHIKV from both entering and exiting cells, whereas prior studies of neutralizing antibodies to CHIKV and multiple other classes of viruses have focused on the capacity to block viruses from entering a cell.